Current Report Filing (8-k)
December 12 2018 - 8:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 12, 2018
SIENNA BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38155
|
|
27-3364627
|
(State or Other Jurisdiction
of Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
30699 Russell Ranch Road, Suite 140
Westlake Village, CA 91362
(Address of principal executive office, including Zip Code)
Registrants telephone number, including area code: (818)
629-2256
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 8.01 Other Events.
On December 12, 2018, Sienna Biopharmaceuticals, Inc. announced that it expects to report results from all three pivotal trials with
SNA-001
for the reduction of light-pigmented hair, as well as the results from the remaining pivotal trial with
SNA-001
in acne, together in late January or early February
2019.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SIENNA BIOPHARMACEUTICALS, INC.
|
|
|
|
|
Date: December 12, 2018
|
|
|
|
By:
|
|
/s/ Timothy K. Andrews
|
|
|
|
|
Name:
|
|
Timothy K. Andrews
|
|
|
|
|
Title:
|
|
General Counsel and Secretary
|
Sienna Biopharmaceuticals (NASDAQ:SNNA)
Historical Stock Chart
From Apr 2024 to May 2024
Sienna Biopharmaceuticals (NASDAQ:SNNA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Sienna Biopharmaceuticals Inc (NASDAQ): 0 recent articles
More Sienna Biopharmaceuticals, Inc. News Articles